Atara Biotherapeutics (ATRA) Interest Expenses (2022 - 2026)

Atara Biotherapeutics has reported Interest Expenses for 5 years, with the latest figure at $830000.0 in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 18.39% year-over-year to $830000.0; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (down 19.51% YoY), and the FY2025 full-year result was $3.8 million, down 17.83% from the prior year.
• Interest Expenses for Q1 2026 stood at $830000.0, down from $894000.0 in the prior quarter.
• The five-year high for Interest Expenses was $1.4 million in Q3 2023, with the low at $4000.0 in Q1 2022.
• Historically, Interest Expenses has averaged $876176.5 across 5 years, with a median of $1.0 million in 2024.
• Annual changes were most pronounced in 2023 — Interest Expenses soared 33300.0% — and 2025, when it dropped 23.16%.
• Atara Biotherapeutics' Interest Expenses stood at $117000.0 in 2022, then soared by 905.13% to $1.2 million in 2023, then decreased by 13.52% to $1.0 million in 2024, then retreated by 12.09% to $894000.0 in 2025, then declined by 7.16% to $830000.0 in 2026.
• The last three Interest Expenses figures came in at $830000.0 (Q1 2026), $894000.0 (Q4 2025), and $909000.0 (Q3 2025), per Business Quant data.